XOMA Royalty Corporation Stock Price, News & Analysis

XOMA Corporation (Nasdaq: XOMA) announced cash dividends for its Series A and Series B Cumulative Preferred Stock. Holders of the Series A stock will receive a dividend of $0.53906 per share, while holders of Series B depositary shares will receive $0.52344 each. These dividends will be paid on January 17, 2023, to shareholders on record as of January 4, 2023. XOMA operates as a biotechnology royalty aggregator, managing a diverse portfolio of over 70 assets related to therapeutic candidates, which it licenses to pharmaceutical companies.

XOMA Corporation has acquired the rights to ebopiprant from ObsEva for $15 million, which includes the Organon License and associated patent estate. The deal allows XOMA to potentially earn up to $475 million in development, regulatory, and sales milestones, plus royalties in the low- to mid-teens upon commercialization. This acquisition marks XOMA's expansion into women's health therapeutics. Ebopiprant has shown promise in reducing preterm labor, with positive results in clinical trials.

XOMA Corporation (Nasdaq: XOMA) announced key financial updates for Q3 2022, reporting total revenues of $0.5 million, down from $0.9 million in Q3 2021. The decline was mainly due to a lack of milestone revenue compared to the previous year. XOMA received its first royalty payment of $0.5 million from Roche related to VABYSMO® sales and also secured $2.5 million from Kuros following Regeneron’s acquisition of Checkmate Pharmaceuticals. The company ended Q3 with $78.3 million cash and no debt, despite a net loss of $4.2 million.

XOMA Corporation (Nasdaq: XOMA) announced cash dividends for its Series A and Series B Cumulative Preferred Stock. Holders of the 8.625% Series A stock will receive $0.53906 per share, while those with the 8.375% Series B stock will receive $0.52344 per depositary share. These dividends are payable on approximately October 17, 2022, to shareholders on record by October 3, 2022. XOMA operates as a biotechnology royalty aggregator, having acquired rights to over 70 assets linked to therapeutic candidates, providing funding to biotechs for their R&D initiatives.

XOMA Corporation will have its CEO, Jim Neal, present at the H.C. Wainwright 24th Annual Global Investment Conference on September 12, 2022, at 10:00 AM ET. The conference aims to highlight XOMA's role as a biotechnology royalty aggregator, helping companies enhance human health by acquiring future economic rights linked to pre-commercial therapeutic candidates. A live stream of the presentation will be accessible here and on XOMA's website. A replay will be available for 90 days post-event.

XOMA Corporation reported its second quarter 2022 financial results, achieving total revenues of $1.0 million, up from $0.9 million in Q2 2021. The net loss widened to $4.7 million compared to $2.2 million in the prior year. Cash at the end of June stood at $83.2 million, with no debt, which management believes will sustain operations for several years. The acquisition of Checkmate Pharmaceuticals resulted in a $2.5 million payment to XOMA, while Rezolute and Day One plan to advance to Phase 3 clinical trials, signaling positive progress in their pipelines.

XOMA Corporation (Nasdaq: XOMA) has announced cash dividends for holders of its Series A and B Cumulative Preferred Stock. Shareholders of the 8.625% Series A stock will receive $0.53906 per share, while holders of the 8.375% Series B stock will receive $0.52344 per depositary share. The dividends are scheduled for payment on July 15, 2022, to shareholders on record by July 1, 2022. XOMA plays a significant role as a biotechnology royalty aggregator, managing over 70 assets related to therapeutic candidates, providing crucial funding for biotech advancement.

XOMA Corporation, a biotechnology royalty aggregator, announced that its Chairman and CEO, Jim Neal, will present at the H.C. Wainwright Global Investment Conference on May 25, 2022, at 10:00 AM ET. The presentation will be accessible online and archived for 90 days post-event. XOMA focuses on acquiring potential future earnings from pre-commercial therapeutic candidates, providing non-dilutive funding to sellers. The company's portfolio includes over 70 assets associated with drug products in development, underscoring its impact on improving human health.

XOMA Corporation (Nasdaq: XOMA) reported a strong financial performance for Q1 2022, with total revenues of $3.1 million, up from $0.4 million in Q1 2021. This increase was propelled by a $2 million milestone from Rezolute for the RZ358 study. The company concluded Q1 2022 with cash and restricted cash totaling $88.6 million and no debt. Notably, XOMA recognized a net loss of $2.3 million, a significant improvement compared to a $7.4 million loss in the prior year. The firm remains optimistic about its financial stability and future operations.